NYSE: HAE · Medical Devices
Haemonetics (HAE) fair value: undervalued or overvalued?
As of 26 Sep 2026, Faircurve's model values Haemonetics (HAE) at $106.81 a share. The stock last closed at $104.68, which puts the model's fair value 2.0% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. Haemonetics Corporation.
Faircurve Insights · 26 Sep 2026
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital.
Faircurve's model found a fair value of $106.81 a share on 26 Sep 2026, the midpoint of 2,000 simulations. The previous run on 19 Sep 2026 gave $109.26, a move of -2.2%. The calibrated range over 63 trading days is $89.61 to $130.24, built from the fair value, and ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium.
The overall quality score against comparable companies is 69 out of 100. The model compares it with Integer Holdings Corporation (ITGR), Neogen Corporation (NEOG), Glaukos Corporation (GKOS), Insulet Corp. (PODD), Bruker Corporation (BRKR), and UFP Technologies, Inc. (UFPT). The moves around the last 8 earnings reports show a median size of 13.3%, ignoring direction.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give HAE?
The calibrated range for HAE over 63 trading days is $89.61 to $130.24. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $77.85 to $143.07. In 52% of the simulations the fair value came out above the price the model ran on.
How does HAE score on business quality?
Haemonetics's overall quality score is 69 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 75 | 10.1%ROIC | 3.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | 3.02xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 39 | -2.0%Revenue growth, trailing | 8.4% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 96 | 3.7%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 23 | 3.64xNet debt / EBITDA | 1.95x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 65 | 1.5 ptsEBITDA margin downside volatility, 5y | 1.4 pts |
How does HAE compare with similar companies?
The companies in medical devices closest to Haemonetics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ITGR Integer Holdings Corporation | $126.45 | $118.83 | -6.0% | Fairly valued |
| LIVN LivaNova PLC | $75.07 | $76.95 | +2.5% | Low evidence grade |
| NEOG Neogen Corporation | $12.15 | $12.06 | -0.7% | Fairly valued |
| TMDX TransMedics Group, Inc. | $79.80 | $85.59 | +7.3% | Low evidence grade |
| GKOS Glaukos Corporation | $163.75 | $147.85 | -9.7% | Fairly valued |
| PODD Insulet Corp. | $131.69 | $142.34 | +8.1% | Fairly valued |
| BRKR Bruker Corporation | $63.24 | $68.13 | +7.7% | Fairly valued |
| UFPT UFP Technologies, Inc. | $300.70 | $275.24 | -8.5% | Fairly valued |
When does HAE report earnings, and how has the stock reacted?
Haemonetics's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 13.6% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How HAE moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 13.3%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | +5.1% |
| 7 May 2026 | +4.7% |
| 5 Feb 2026 | -10.0% |
| 6 Nov 2025 | +34.8% |
| 7 Aug 2025 | -28.7% |
| 8 May 2025 | +14.8% |
| 6 Feb 2025 | -16.7% |
| 7 Nov 2024 | +11.8% |
Haemonetics at a glance
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital.
- Market value
- $4.8B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $1.5B
- Consensus revenue growth, next fiscal year
- +6.2%
- Analysts with estimates
- 8
- Beta to the US market
- -0.19
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Haemonetics on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for HAE was $109.26. As of 26 Sep 2026 it is $106.81, a change of -2.2%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Haemonetics's valuation
Is Haemonetics stock undervalued or overvalued?
On Faircurve's model, HAE reads as Fairly valued as of 26 Sep 2026. The model's fair value is $106.81 a share against a last close of $104.68, a gap of +2.0%.
What is HAE's fair value?
$106.81 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $77.85 to $143.07.
What price range does the model give HAE?
$89.61 to $130.24 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Haemonetics report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has HAE moved on past earnings reports?
Across its last 8 reports the median two session move was 13.3%, ignoring direction. The largest was +34.8% around the report of 6 Nov 2025.
How confident is the model in this valuation?
The model's evidence grade for HAE is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.